Amplitude-Modulated Radiofrequency Electromagnetic Fields (AM RF EMF) in Combination With Fruquintinib in Refractory Metastatic Colorectal Cancer

This study is testing a combination of electromagnetic field therapy (a non-invasive device treatment) and a targeted oral drug called fruquintinib in people with advanced colorectal cancer that has stopped responding to multiple prior treatments. **You may be eligible if...** - You have confirmed metastatic colorectal cancer - Your tumor has been tested for RAS, BRAF, MSI/MMR, and HER2 markers - You have already tried and progressed on standard chemotherapy regimens (fluoropyrimidine, oxaliplatin, irinotecan-based) and anti-VEGF therapy - If your RAS is wild-type, you have also tried anti-EGFR therapy - Your cancer is measurable on scans **You may NOT be eligible if...** - You have uncontrolled high blood pressure - You have a history of stomach or intestinal ulcers, active colitis, or a risk of GI bleeding or perforation - You have had significant bleeding from any site in the past 2 months - You have a history of blood clots or serious cardiovascular events Talk to your doctor to see if this trial is right for you.